CATX (Perspective Therapeutics) Total Debt per Share: $0.04 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CATX Perspective Therapeutics Inc CATX
31 GF Score
Price $3.00
! 2 Warning Signs
View Full Analysis

What is Perspective Therapeutics Total Debt per Share?

Perspective Therapeutics CATX -0.33% 31 Total Debt per Share is $0.04 as of Mar. 2026. GuruFocus rates CATX with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.

$0.04 (As of Mar. 2026)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Perspective Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2026 was $0.04.


Perspective Therapeutics Total Debt per Share Historical Data

* Premium members only.

The historical data trend for Perspective Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Perspective Therapeutics Total Debt per Share Chart

Perspective Therapeutics Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Dec23 Dec24
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.15 0.06 0.04 0.09 0.06

Perspective Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.05 0.04 0.04
CATX
31GF Score
Perspective Therapeutics Inc CATX
Total Debt per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Perspective Therapeutics Total Debt per Share Calculation

Perspective Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Perspective Therapeutics's Total Debt Per Share for the quarter that ended in Mar. 2026 is calculated as:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Debt per Share →
What does a Total Debt per Share of $0.04 mean?
Perspective Therapeutics (CATX) has a Total Debt per Share of $0.04 as of Mar. 2026. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Perspective Therapeutics and its competitors.
Is Perspective Therapeutics' Total Debt per Share too high?
Perspective Therapeutics' current Total Debt per Share is $0.04. Overall, Perspective Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Perspective Therapeutics' Total Debt per Share compare to CV and LAB?
Perspective Therapeutics' Total Debt per Share of $0.04 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Debt per Share for a Medical Devices & Instruments company?
A good Total Debt per Share depends on the Medical Devices & Instruments industry context. However, Total Debt per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Debt per Share mean?
A high Total Debt per Share can signal that a stock is expensive relative to its fundamentals. Total debt per share equals the per-share value of a company's long-term and short-term debt. View historical data on Perspective Therapeutics and its competitors. Perspective Therapeutics's current Total Debt per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Perspective Therapeutics stock overvalued right now?
Perspective Therapeutics (CATX) has a current Total Debt per Share of $0.04. The current Total Debt per Share is $0.04. Perspective Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Debt per Share calculated?
Total Debt per Share is calculated from a company's financial statements. For Perspective Therapeutics (CATX), the current Total Debt per Share is $0.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Perspective Therapeutics Business Description

Other Exchanges AAJ0:Germany
Address 2401 Elliott Avenue, Suite 320, Seattle, WA, USA, 98121
Perspective Therapeutics Inc is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha-emitting isotope Lead-212 (212Pb) to deliver powerful radiation specifically to cancer cells via specialized targeting moieties.
31GF Score

Get the complete analysis for CATX

Total Debt per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.00
Price